Drug intelligence / Profile preview

NDV vaccine

Development stage: Preclinical
Lead developer: Gamma Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal, Ophthalmic, Oral, Intramuscular, Subcutaneous

Overview

NDV vaccine is a **preclinical whole inactivated virus vaccine** being developed by **Gamma Vaccines** for prevention of **Newcastle Disease Virus infection** and potentially **avian influenza** in veterinary settings. The candidate uses Gamma Vaccines' **gamma-irradiation photon inactivation platform**, which is intended to inactivate intact virus while preserving structural and antigenic features that may support both **humoral and cellular immune responses**. Gamma Vaccines has indicated that this NDV vaccine program was acquired from the **University of Adelaide** in October 2024 and is part of its early-stage animal health vaccine pipeline.

Other names: Newcastle Disease Virus vaccineNDV avian vaccine

Beyond the preview

Go deeper on NDV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDV vaccine.

Explore the full profile